Post Covid-19 Cardiopulmonary and Immunological Changes
covid-19
Cardiopulmonary and Immunological Impacts of Covid-19 in a Cohort of Survivors
1 other identifier
observational
100
1 country
1
Brief Summary
Study rationale and aim: Resolving the COVID-19 pandemic quickly hinges on a crucial factor: how well a person's immune system remembers SARS-CoV-2, the virus behind the disease, after an infection has resolved and the patient is back in good health. This phenomenon, called immune memory, helps our bodies avoid reinfection by a bug persons have had before and influences the potency of life-saving treatments and vaccines. Also, the new coronavirus causes cardiac and pulmonary inflammation. So, our study planned to measure the cardiopulmonary and immunological changes in treated COVID-19 patients. Specific objectives: Measurement the duration of existence of COVID-19 IgM and IgG antibody in patient's plasma, detection of cardiac changes, pulmonary radiological and functional changes after COVID-19 infection. This could help detection of functional impairment in COVID-19 survivors which may have economic and social impact. Also, investigator will assess possible protective immune response following infection which may affect vaccination schedule. Methods: One hundred RT- PCR positive COVID-19 patients will be enrolled. HRCT chest, lateral flow immunoassay, spirometry, DLCO and Echo will be done on after 3, 6 and 12 months of discharge.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started May 2020
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 11, 2020
CompletedStudy Start
First participant enrolled
May 11, 2020
CompletedFirst Posted
Study publicly available on registry
May 14, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 10, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
October 10, 2021
CompletedMay 19, 2020
May 1, 2020
1.2 years
May 11, 2020
May 15, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
measurement of pulmonary function changes either obstructive or restrictive also lung diffusion and if there is remaining interstitial fibrosis
pulmonary function include lung volumes in millimetre and lung capacities
12 months
measurement for cardiac function and ejection fraction changes and if there is changes in pulmonary artery pressure
Ejection fraction ,myocardial contractility,pulmonary artery pressure
12 months
Secondary Outcomes (1)
assessment of IGM and IGG level and if there is immunological changes
12 months
Eligibility Criteria
covid-19 pcr positive survivors
You may qualify if:
- pcr positive for covid -19 who are survived
You may not qualify if:
- dead patient uncooperative
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Mansoura faculty of medicine
Al Mansurah, Dakahlia Governorate, 35511, Egypt
Related Publications (14)
Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, Lit LC, Hui DS, Chan MH, Chung SS, Sung JJ. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004 Apr;136(1):95-103. doi: 10.1111/j.1365-2249.2004.02415.x.
PMID: 15030519BACKGROUNDVashist SK. In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends. Diagnostics (Basel). 2020 Apr 5;10(4):202. doi: 10.3390/diagnostics10040202.
PMID: 32260471BACKGROUNDPark WB, Jun KI, Kim G, Choi JP, Rhee JY, Cheon S, Lee CH, Park JS, Kim Y, Joh JS, Chin BS, Choe PG, Bang JH, Park SW, Kim NJ, Lim DG, Kim YS, Oh MD, Shin HS. Correlation between Pneumonia Severity and Pulmonary Complications in Middle East Respiratory Syndrome. J Korean Med Sci. 2018 May 10;33(24):e169. doi: 10.3346/jkms.2018.33.e169. eCollection 2018 Jun 11.
PMID: 29892209BACKGROUNDOudit GY, Kassiri Z, Jiang C, Liu PP, Poutanen SM, Penninger JM, Butany J. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 2009 Jul;39(7):618-25. doi: 10.1111/j.1365-2362.2009.02153.x. Epub 2009 May 6.
PMID: 19453650BACKGROUNDOoi GC, Khong PL, Muller NL, Yiu WC, Zhou LJ, Ho JC, Lam B, Nicolaou S, Tsang KW. Severe acute respiratory syndrome: temporal lung changes at thin-section CT in 30 patients. Radiology. 2004 Mar;230(3):836-44. doi: 10.1148/radiol.2303030853.
PMID: 14990845BACKGROUNDOng KC, Ng AW, Lee LS, Kaw G, Kwek SK, Leow MK, Earnest A. 1-year pulmonary function and health status in survivors of severe acute respiratory syndrome. Chest. 2005 Sep;128(3):1393-400. doi: 10.1378/chest.128.3.1393.
PMID: 16162734BACKGROUNDNgai JC, Ko FW, Ng SS, To KW, Tong M, Hui DS. The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. Respirology. 2010 Apr;15(3):543-50. doi: 10.1111/j.1440-1843.2010.01720.x. Epub 2010 Mar 19.
PMID: 20337995BACKGROUNDJackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood. 2019 Feb 28;133(9):906-918. doi: 10.1182/blood-2018-11-882993. Epub 2019 Jan 14.
PMID: 30642917BACKGROUNDKetai L, Paul NS, Wong KT. Radiology of severe acute respiratory syndrome (SARS): the emerging pathologic-radiologic correlates of an emerging disease. J Thorac Imaging. 2006 Nov;21(4):276-83. doi: 10.1097/01.rti.0000213581.14225.f1.
PMID: 17110851BACKGROUNDHui DS, Wong KT, Ko FW, Tam LS, Chan DP, Woo J, Sung JJ. The 1-year impact of severe acute respiratory syndrome on pulmonary function, exercise capacity, and quality of life in a cohort of survivors. Chest. 2005 Oct;128(4):2247-61. doi: 10.1378/chest.128.4.2247.
PMID: 16236881BACKGROUNDHuang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
PMID: 31986264BACKGROUNDEngelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013 Jan;13(1):34-45. doi: 10.1038/nri3345. Epub 2012 Dec 7.
PMID: 23222502BACKGROUNDDas KM, Lee EY, Singh R, Enani MA, Al Dossari K, Van Gorkom K, Larsson SG, Langer RD. Follow-up chest radiographic findings in patients with MERS-CoV after recovery. Indian J Radiol Imaging. 2017 Jul-Sep;27(3):342-349. doi: 10.4103/ijri.IJRI_469_16.
PMID: 29089687BACKGROUNDCameron MJ, Bermejo-Martin JF, Danesh A, Muller MP, Kelvin DJ. Human immunopathogenesis of severe acute respiratory syndrome (SARS). Virus Res. 2008 Apr;133(1):13-9. doi: 10.1016/j.virusres.2007.02.014. Epub 2007 Mar 19.
PMID: 17374415BACKGROUND
Related Links
Study Officials
- PRINCIPAL INVESTIGATOR
Tamer A Elhadidy, MD
assistant professor
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 18 Months
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 11, 2020
First Posted
May 14, 2020
Study Start
May 11, 2020
Primary Completion
July 10, 2021
Study Completion
October 10, 2021
Last Updated
May 19, 2020
Record last verified: 2020-05
Data Sharing
- IPD Sharing
- Will not share
no plan for sharing data for other researchers